| (1) |
Clinical guideline, part 1. Screening for thyroid disease. American College
of Physicians. Ann Intern Med. 1998; 129: 141-3. |
| (2) |
Helfand M, Redfern CC. Clinical guideline, part
2. Screening for thyroid disease: an update. Ann Intern Med. 1998; 129:
144-58. |
| (3) |
Diekman T, Lansberg PJ, Kastelein JJ, Wiersinga WM. Prevalence
and correction of hypothyroidism in a large cohort of patients referred
for dyslip-idemia. Arch Intern Med. 1995; 155: 1490-5. |
| (4) |
Vanderpump MP, Tunbridge WM, French JM, Appleton D, Bates D, Clark
F, et al. The incidence of thyroid disorders in the community: a twenty-year
follow-up of the Whickham Survey. Clin Endocrinol. 1995; 43: 55-68. |
| (5) |
Vestergaard H, Laurberg P. Radioiodine and aggravation of Graves'
oph-thalmopathy [Letter]. Lancet. 1989; 2: 47. |
| (6) |
Tallstedt L, Lundell G, Tｿrring O, Wallin G, Ljunggren JG, Blomgren
H, et al. Occurrence of ophthalmopathy after treatment for Graves' hyperthy-roidism.
N Engl J Med. 1992; 326: 1733-8. |
| (7) |
Bartalena L, Marcocci C, Bogazzi F, Manetti L, Tanda ML, Dell'Unto
E, et al. Relation between therapy for hyperthyroidism and the course
of Graves' ophthalmopathy. N Engl J Med. 1998; 338: 73-8. |
| (8) |
Bartalena L, Marcocci C, Tanda ML, Manetti L, Dell'Unto L, Bartolomei
MP, et al. Cigarette smoking and treatment outcomes in Graves ophthal-mopathy.
Ann Intern Med. 1998; 129: 632-5. |
| (9) |
Romaldini JH, Bromberg N, Werner RS, Tanaka LM, Rodrigues HF, Werner
MC, et al. Comparison of effects of high and low dosage regimens of
antithyroid drugs in the management of Graves' disease. J Clin Endocrinol
Metab. 1983; 57: 563-70. |
| (10) |
Hashizume K, Ichikawa K, Sakurai A, Suzuki S, Takeda T, Kobayashi M,
et al. Administration of thyroxine in treated Graves' disease. Effects
on the level of antibodies to thyroid-stimulating hormone receptors and
on the risk of recurrence of hyperthyroidism. N Engl J Med. 1991; 324: 947-53. |
| (11) |
Tamai H, Hayaki I, Kawai K, Komaki G, Matsubayashi S, Kuma K, et al.
Lack of effect of thyroxine administration on elevated thyroid stimulating
hormone receptor antibody levels in treated Graves' disease patients. J
Clin Endocrinol Metab. 1995; 80: 1481-4. |
| (12) |
McIver B, Rae P, Beckett G, Wilkinson E, Gold A, Toft A. Lack of
effect of thyroxine in patients with Graves' hyperthyroidism who are treated
with an antithyroid drug. N Engl J Med. 1996; 334: 220-4. |
| (13) |
Lucas A, Salinas I, Ruis F, Pizarro E, Granada ML, Foz M, et al.
Medical therapy of Graves' disease: does thyroxine prevent recurrence of
hyperthy-roidism? J Clin Endocrinol Metab. 1997; 82: 2410-3. |
| (14) |
Rittmaster RS, Abbott EC, Douglas R, Givner ML, Lehmann L, Reddy S,
et al. Effect of methimazole, with or without L-thyroxine, on remission
rates in Graves' disease. J Clin Endocrinol Metab. 1998; 83: 814-8. |
| (15) |
Imseis RE, Vanmiddlesworth L, Massie JD, Bush AJ, Vanmiddlesworth NR.
Pretreatment with propylthiouracil but not methimazole reduces the therapeutic
efficacy of iodine-131 in hyperthyroidism. J Clin Endocrinol Metab. 1998;
83: 685-7. |
| (16) |
Bunevicius R, Kazanavicius G, Zalinkevicius R, Prange AJ Jr. Effects
of thyroxine as compared with thyroxine plus triiodothyronine in patients
with hypothyroidism. N Engl J Med. 1999; 340: 424-9. |
| (17) |
Toft AD. Thyroid hormone replacement-one hormone or two? [Editorial]
N Engl J Med. 1999; 340: 469-70. |
| (18) |
Tan GH, Gharib H. Thyroid incidentalomas: management approaches
to nonpalpable nodules discovered incidentally on thyroid imaging. Ann Intern
Med. 1997; 126: 226-31. |
| (19) |
Khurana KK, Richards VI, Chopra PS, Izquierdo R, Rubens D, Meson-ero
C. The role of ultrasonography-guided fine-needle aspiration biopsy
in the management of nonpalpable and palpable thyroid nodules. Thyroid.
1998; 8: 511-5. |
| (20) |
Hagag P, Strauss S, Weiss M. Role of ultrasound-guided fine-needle
aspi-ration biopsy in evaluation of nonpalpable thyroid nodules. Thyroid.
1998; 8: 989-95. |
| (21) |
Greenspan SL, Greenspan FS. The effect of thyroid hormone on skeletal
integrity. Ann Intern Med. 1999; 130: 750-8. |
| (22) |
Ching GW, Franklyn JA, Stallard TJ, Daykin J, Sheppard MC, Gam-mage
MD. Cardiac hypertrophy as a result of long-term thyroxine therapy and
thyrotoxicosis. Heart. 1996; 75: 363-8. |
| (23) |
Zelmanovitz F, Genro S, Gross JL. Suppressive therapy with levothyroxine
for solitary thyroid nodules: a double-blind controlled clinical study and
cu-mulative meta-analyses. J Clin Endocrinol Metab. 1998; 83: 3881-5. |